Yehiel Tal Thank you for the question. Itâs a great question. The concept is the following. We will produce the scaffolds as it will mimic the gut tissue and we will gather with the microfluidic chip and the matrix cells that we will develop, so we can do a multi-channel kind of testing. We will provide all of this to our collaborator, which should be a CRO that will take the biopsies from the patient, collect the biopsies and save the scaffolds and do the testing, so this is the concept. Swayampakula Ramak ...

Conference Call Participants Ben Haynor - Alliance Global Partners Swayampakula Ramakanth - H.C. Wainwright Operator Welcome to the CollPlant Biotechnologies Investor Conference Call to discuss Financial Results for the First Quarter of 2023 and Corporate Updates. I'd now like to turn the call over to your host, Dory Kurowski of LifeSci Advisors. Please go ahead. Dory Kurowski Good morning. I would like to welcome everyone to CollPlant Biotechnologies' financial results conference call for the first quarter ...

Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and it ...

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q4 2022 Earnings Conference Call March 29, 2023 10:00 AM ET Dory Kurowski - LifeSci Advisors Eran Rotem - Chief Financial Officer Ben Haynor - Alliance Global Partners Operator Now, I'd like to turn the call over to Dory Kurowski of LifeSci Advisors. Please go ahead ma'am. Good morning. I would like to welcome everyone to CollPlant Biotechnologies' first financial results conference call for the full-year ended December 31, 2022. With us on the call today from Co ...

● attract and retain skilled personnel; ● create additional infrastructure to support our operations as a public company; and ● experience any delays or encounter issues with any of the above. The net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. In any particular quarter or quarters, our operating results could be below the expectations of secu ...

Exhibit 99.1 Collplant Biotechnologies Announces Full-Year Financial Results For 2022 and Provides Corporate Update ● Continued advancement of strategic collaboration with AbbVie to develop dermal and soft tissue filler products using CollPlant's recombinant human (rh)Collagen ● Additional large-animal study planned in H2 2023 to further 3D bioprinted regenerative breast implant program ● Conference call to be held on March 29, 2023 at 10:00 am U.S. ET; Dial-in information herein Rehovot, Israel, March 29, ...

Exhibit 99.1 CollPlant Biotechnologies Provides Business Updates and Third Quarter 2022 Financial Results ● Partnership with AbbVie to co-develop rhCollagen-based dermal and soft tissue fillers continues to advance according to plan ● Co-developing 3D bioprinted human intestine model ("Gut-on-a-Chip") for drug discovery and personalized treatment of ulcerative colitis with Tel-Aviv University and SHEBA Hospital ● 3D bioprinted regenerative breast implant program on track for Q1 2023 readout of large animal ...

Exhibit 99.2 COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2022 COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2022 TABLE OF CONTENTS | --- | --- | |-----------------------------------------------------------------------------------|----------------| | CONDENSED CONSOLIDATED FINANCIAL STATEMENTS: | Page | | Condensed Consolidated Balance Sheets | F-2 - F-3 | | Condensed Consolidated Statements of C ...

Exhibit 99.1 CollPlant Biotechnologies Provides Business Updates and Fiscal Year 2021 Financial Results ● Record revenues in 2021 of $15.6 million versus $6.1 million in 2020 ● Continued progress of strategic agreement with AbbVie to develop dermal and soft tissue filler products using CollPlant's rhCollagen ● Company to advance 3D bioprinted regenerative breast implant program with launch of large animal study expected in Q2 ● Strong balance sheet with $43.3 million cash position, as of December 31, 2021 R ...

Exhibit 99.1 CollPlant Biotechnologies Provides Business Updates and Fiscal Year 2021 Financial Results ● Record revenues in 2021 of $15.6 million versus $6.1 million in 2020 ● Continued progress of strategic agreement with AbbVie to develop dermal and soft tissue filler products using CollPlant's rhCollagen ● Company to advance 3D bioprinted regenerative breast implant program with launch of large animal study expected in Q2 ● Strong balance sheet with $43.3 million cash position, as of December 31, 2021 R ...